• 1
    Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005; 19: 2025-2029.
  • 2
    Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony–stimulating factor in children and adolescents with acute myeloid leukemia: results of AML–BFM 98. J Clin Oncol. 2006; 24: 4499-4506.
  • 3
    Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG–2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008; 111: 1044-1053.
  • 4
    Carrera CJ, Terai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990; 86: 1480-1488.
  • 5
    Kearns CM, Blakley RL, Santana VM, Crom WR. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 1994; 54: 1235-1239.
  • 6
    Santana VM, Mirro JJr, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992; 10: 364-370.
  • 7
    Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001; 19: 2804-2811.
  • 8
    Crews KR, Gandhi V, Srivastava DK, et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002; 20: 4217-4224.
  • 9
    Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973; 33: 2834-2836.
  • 10
    Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK. Altered formation of topotecan–stabilized topoisomerase I–DNA adducts in human leukemia cells. Blood. 1997; 89: 2098-2104.
  • 11
    Furman WL, Stewart CF, Kirstein M, et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol. 2002; 20: 1617-1624.
  • 12
    Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of 2 schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998; 16: 2233-2237.
  • 13
    Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989; 45: 925-937.
  • 14
    Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res. 2003; 9: 633-640.
  • 15
    Rowinsky EK, Kaufmann SH, Baker SD, et al. A phase I and pharmacological study of topotecan infused over 30 minutes for 5 days in patients with refractory acute leukemia. Clin Cancer Res. 1996; 2: 1921-1930.
  • 16
    Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol. 1992; 10: 1514-1518.
  • 17
    Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008; 113: 376-382.
  • 18
    Abrahamsson J, Clausen N, Gustafsson G, et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol. 2007; 136: 229-236.
  • 19
    Aladjidi N, Auvrignon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003; 21: 4377-4385.
  • 20
    Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003; 21: 2940-2947.
  • 21
    Meshinchi S, Leisenring WM, Carpenter PA, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant. 2003; 9: 706-713.
  • 22
    Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105: 3051-3057.
  • 23
    Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2007; 13: 1-25.